Ibio Inc (IBIO)

$2.24 -0.06 (-2.61%)
Market Cap 47.22M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.01
Volume 914,800
Avg Vol 6,798,622
Day's Range N/A - N/A
Shares Out 22.49M
Stochastic %K 47%
Beta 1.14
Analysts Strong Sell
Price Target $4.77

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
Get_r_done
Get_r_done Feb. 3 at 10:20 PM
$IBIO Still seeing the Bull Flag on the Daily & a double bottom on the lower time frames. I smell a good 1st qrtr report coming. For what it's worth... The Phase 1 is to happen 1st half of 2026 (calendar), or 1st half of 2026 (Fiscal). We're now in the 2nd quarter of Fiscal '2
1 · Reply
WenABVEAudit
WenABVEAudit Feb. 3 at 7:35 PM
$IBIO waiting
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Feb. 3 at 1:22 PM
$IBIO response after the website was screwed up and got fixed
1 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Feb. 3 at 12:50 PM
$FUBO I’m sorry 😞 to hear RS. Sucks I been there thank god I bought $IBIO over a gamble on earnings fubo. Go to ibio it’s better and ready today
1 · Reply
504_coonazz
504_coonazz Feb. 3 at 4:55 AM
$IBIO where’s all the OG ibios where’s Tom at now? We should jump his azz
2 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 3 at 1:32 AM
$IBIO this is still around?
0 · Reply
TortillaDePatata
TortillaDePatata Feb. 2 at 9:08 PM
$IBIO Come on!!!!!💪💪💪💪💪💪💪💪
0 · Reply
dcpanda
dcpanda Feb. 2 at 9:07 PM
$IBIO First Target: 2.5 Second Target: 2.9 to 3.2
1 · Reply
DancingQueen69
DancingQueen69 Feb. 2 at 7:20 PM
$IBIO I bought a nice position here during last days. 52k and VWAP 2.13$. 6$ would satisfy me ❤️
0 · Reply
luxm3
luxm3 Feb. 2 at 6:25 PM
$IBIO ready to go above 3...
0 · Reply
Latest News on IBIO
iBio Announces $26 Million Private Placement

Jan 9, 2026, 7:00 AM EST - 25 days ago

iBio Announces $26 Million Private Placement

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:15 PM EST - 2 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 2 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 3 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 3 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 3 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 5 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 5 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 6 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 6 months ago

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 8 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 8 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 8 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 9 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 9 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 10 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 10 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 10 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 3 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 3 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Feb 16, 2023, 4:48 PM EST - 3 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

iBio Announces Proposed Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

Get_r_done
Get_r_done Feb. 3 at 10:20 PM
$IBIO Still seeing the Bull Flag on the Daily & a double bottom on the lower time frames. I smell a good 1st qrtr report coming. For what it's worth... The Phase 1 is to happen 1st half of 2026 (calendar), or 1st half of 2026 (Fiscal). We're now in the 2nd quarter of Fiscal '2
1 · Reply
WenABVEAudit
WenABVEAudit Feb. 3 at 7:35 PM
$IBIO waiting
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Feb. 3 at 1:22 PM
$IBIO response after the website was screwed up and got fixed
1 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Feb. 3 at 12:50 PM
$FUBO I’m sorry 😞 to hear RS. Sucks I been there thank god I bought $IBIO over a gamble on earnings fubo. Go to ibio it’s better and ready today
1 · Reply
504_coonazz
504_coonazz Feb. 3 at 4:55 AM
$IBIO where’s all the OG ibios where’s Tom at now? We should jump his azz
2 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 3 at 1:32 AM
$IBIO this is still around?
0 · Reply
TortillaDePatata
TortillaDePatata Feb. 2 at 9:08 PM
$IBIO Come on!!!!!💪💪💪💪💪💪💪💪
0 · Reply
dcpanda
dcpanda Feb. 2 at 9:07 PM
$IBIO First Target: 2.5 Second Target: 2.9 to 3.2
1 · Reply
DancingQueen69
DancingQueen69 Feb. 2 at 7:20 PM
$IBIO I bought a nice position here during last days. 52k and VWAP 2.13$. 6$ would satisfy me ❤️
0 · Reply
luxm3
luxm3 Feb. 2 at 6:25 PM
$IBIO ready to go above 3...
0 · Reply
Batman_the_legend
Batman_the_legend Feb. 2 at 5:17 PM
$IBIO The roaring Lion picked IBIO under $1.10 now just started $DRMA at strong buy 10x . Buy a little if you can. sold $MOVE in $EVTV https://www.moomoo.com/stock/DRMA-US/community?_ftsdk=1767210349494147&_fttime=1770051441&chain_id=f37s0EKZJEb-h4.1ko1lpm&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A27%7D
2 · Reply
dcpanda
dcpanda Feb. 2 at 3:55 PM
$IBIO Breakout confirmed if we can close above 2.25 🍻
0 · Reply
luxm3
luxm3 Feb. 2 at 3:53 PM
$IBIO in at 2.18... see you above 4...good buy signal
0 · Reply
1Powar
1Powar Feb. 2 at 3:32 PM
$IBIO Schwab
0 · Reply
floyd860
floyd860 Feb. 2 at 2:22 PM
$IBIO E-Trade
0 · Reply
jlld
jlld Feb. 2 at 2:25 AM
$IBIO reliable summary of IBIO’s institutional ownership based on recent filings and public data (as of late 2025–early 2026): 📊 Institutional Ownership (Based on 13F & Ownership Data) • ~7.90 % institutional ownership — this is the figure reported by MarketBeat using SEC 13F filings for institutional holders (the industry’s standard reporting).  • Other public data sources (e.g., TipRanks) show ~9.62 % institutional ownership.  • Some aggregators vary more widely (e.g., a ~34 % figure from Tickergate), but these sources mix hedge funds, VC/PE, and institutions differently and do not always reflect SEC 13F filing
0 · Reply
WZMAN7227
WZMAN7227 Feb. 2 at 1:31 AM
$IBIO Shares held by institutions 60.92%
1 · Reply
1Powar
1Powar Jan. 31 at 3:15 AM
$IBIO what ya ding dongs should be looking into is SilverArc. BUT the TV hasn’t told you yet so you’ll just have to respond with something retarded.
1 · Reply
1Powar
1Powar Jan. 31 at 3:11 AM
$IBIO from a WHILE ago. not new just added.
0 · Reply
1Powar
1Powar Jan. 31 at 1:00 AM
$IBIO gotcha! What are you weasels hiding. Trust you to make a drug but can’t get your site right. Come clean update your investors cowards, or you drugging your wives like Bill Gates? Phase 1 was changed to IND fyi.
2 · Reply
jlld
jlld Jan. 30 at 10:55 PM
$IBIO 0.001 exercise price is symbolic. So: • Cash was received in January • Dilution was known then • Nothing new is happening now ⸻ 2. Why the 11M shares show up now Because of registration rights, not capital need. When sophisticated investors write a check in a private placement, they require: • The company to later register their shares for resale • So they have the option to sell if and when they want That’s what this S-3 is. Key sentence (you posted it, but it matters): “We are not offering any Shares under this prospectus and will not receive any proceeds…” So: • ❌ No new money raised • ❌ No balance-sheet need • ❌ No company-initiated selling This filing simply fulfills a co
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jan. 30 at 11:54 AM
$IBIO
0 · Reply